Best practices in care for menopausal patients: 16 years after the Women's Health Initiative.
Journal
Journal of the American Association of Nurse Practitioners
ISSN: 2327-6924
Titre abrégé: J Am Assoc Nurse Pract
Pays: United States
ID NLM: 101600770
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
pubmed:
26
3
2019
medline:
14
4
2020
entrez:
26
3
2019
Statut:
ppublish
Résumé
The Women's Health Initiative (WHI) was a large, randomized clinical trial funded by the National Institutes of Health to determine whether menopause hormone therapy (MHT) prevented heart disease, breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. Two WHI trials were stopped early, and the findings had a profound effect on the clinical practice guidelines related to postmenopausal health. This article provides an overview of the WHI MHT clinical trials and findings, discusses the early stoppage of the trials and subsequent implications, and details the current nomenclature and treatment options for women transitioning through menopause in light of the WHI. This study is based on a comprehensive literature review and an education activity developed by the American Association of Nurse Practitioners. To best serve patients and individualize therapy, clinicians must provide the best estimate of potential risks or benefits to the individual patient. It is important to balance evidence of symptom relief with long-term risks and benefits that fit the patient's characteristics of family and personal health history. Armed with evidence to support various hormonal and non-hormonal options, well-informed clinicians can counsel women about MHT and potentially avoid negative impact on quality of life.
Identifiants
pubmed: 30908403
doi: 10.1097/JXX.0000000000000186
pii: 01741002-201907000-00009
doi:
Types de publication
Journal Article
Langues
eng
Pagination
420-427Références
Al-Safi Z. A., Santoro N. (2014). Menopausal hormone therapy and menopausal symptoms. Fertility and Sterility, 101, 905–915.
Anderson G. L. L. M., Assaf A. R., Limacher M., Bassford T., Beresford S. A., Black H., …; Writing Group for Women's Health Initiative (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The women's health initiative randomized controlled trial. Journal of the American Medical Association, 291, 1701–1712.
Barrett-Conner E., Dam T. T., Stone K., Harrison S. L., Redline S., Orwoll E. (2008). The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. Journal of Clinical Endocrine Metabolism, 93, 2602–2609.
Bolour S., Braunstein G. (2005). Testosterone therapy in women: A review. International Journal of Impotence Research, 17, 399–408.
Brown S. (2012). Shock, terror and controversy: How the media reacted to the women's health initiative. Climacteric, 15, 275–280.
Corbelli J., Hess R. (2012). Hormone therapy prescribing trends in the decade after the Women's Health Initiative: How patients and providers have found a way to sleep better at night. Menopause, 19, 600–601.
Davis S. R., Wahlin-Jacobsen S. (2015). Testosterone in women—the clinical significance. The Lancet Diabetes and Endocrinology, 3, 980–992.
Ebinger M., Sievers C., Ivan D., Schneider H. J., Stalla G. K. (2009). Is there a neuroendocrinological rationale for testosterone as a therapeutic option for depression? Journal of Psychopharmacology, 23, 841–853.
Elavsky S., McAuley E. (2009). Personality, menopausal symptoms, and physical activity outcomes in middle-aged women. Personality and Individual Differences, 46, 123–128.
Elraiyah T., Sonbol M. B., Wang Z., Khairalseed T., Asi N., Undavalli C., Murad MH. (2014). The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 99, 3543–3550.
Files J. A., Ko M. G., Pruthi S. (2011). Bioidentical hormone therapy. Mayo Clinic Proceedings, 86, 673–680.
Ghazal S., Pal L. (2013). Perspective on hormone therapy 10 years after the WHI. Maturitas, 76, 208–212.
Glaser R., York A. E., Dimitrakakis C. (2010). Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas, 68, 355–361.
Grant M., Marbella A., Wang A., Pines E., Hoag J., Bonnell C., Ziegler K. M., Aronson N. (2015). Prepared by blue cross and blue shield association technology evaluation center evidence-based practice center under contract No. 290-2007-10058-I). AHRQ publication No. 15-EHC005-EF. In Menopausal Symptoms: Comparative Effectiveness of Therapies. Comparative Effectiveness Review No. 147. Rockville, MD: Agency for Healthcare Research and Quality.
Hays J., Hunt J., Hubbell F., Anderson M. G., Limacher M., Allen C., Rossouw J. (2003). The Women's Health Initiative recruitment methods and results. Annals of Epidemiology, 13(9 Suppl), S18–S88.
Kim S., Sim M., Park S. (2015). Association between duration of reproductive lifespan and Framingham risk score in postmenopausal women. Maturitas, 82, 431–435.
LaCroix A., Chlebowski R., Manson J., Aragaki A. K., Johnson K. C., Martin L., …; WHI Investigators. (2011). Health outcomes after stopping conjugated equine estrogens among poistmenopausal women with prior hysterectomy: A randomized controlled trial. Journal of the American Medical Association, 305, 1305–1314.
Luoto R. (2009). Hot flushes and quality of life during menopause. BMC Women's Health, 9, 13.
MacLaren K., Stevenson J. (2012). Primary prevention of cardiovascular disease with HRT. Women and Health, 8, 63–74.
Manson J., Chlebowski M., Stefanick M., Aragaki A., Rossouw J., Prentice R., Wallace R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Journal of the American Medical Association, 310, 1353–1368.
Moolman J. (2006). Unravelling the cardioprotective mechanism of action of estrogens. Cardiovascular Research, 69, 777–780.
North American Menopause Society. (2012). The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause, 19, 257–271.
O'Connell M. B. (1995). Pharmacokinetic and pharmacologic variation between different estrogen products. The Journal of Clinical Pharmacology, 35, 18S.
Pedersen A. T., Ottesen B. (2003). Issues to debate on the Women's Health Initiative (WHI) study: Epidemiology or randomized clinical trials—Time out for hormone replacement therapy studies? Human Reproduction, 18, 2241–2244.
Pinkerton J. V. (2017). Changing the conversation about hormone therapy. Menopause, 24, 991–993.
Pinkerton J. V., Komm B. S., Mirkin S. (2013). Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model. Climacteric, 16, 618–628.
Pinkerton J. V., Santoro N. (2015). Compounded bioidentical hormone therapy: Identifying use trends and knowledge gaps among US women. Menopause, 22, 926–936.
Portman D. J., Gass M. L., & Vulvovaginal Atrophy Terminology Consensus Conference Panel. (2014). Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the international society for the study of Women's sexual health and the North American Menopause Society. Climacteric, 17, 557–563.
Prentice R., Rossouw J., Furberg C., Johnson S., Henderson M., Cummings S., Ettinger S. (1998). Design of the WHI clinical trial and observational study. Control Clinical Trials, 19, 61–109.
Rahn D. D., Carberry C., Sanses T. V., Mamik M. M., Ward R. M., Meriwether K. V., …; Society of Gynecologic Surgeons Systematic Review Group (2014). Vaginal estrogen for genitourinary syndrome of menopause: A systematic review. Obstetrics and Gynecology, 124, 1147.
Rossouw J. E., Anderson G. L., Prentice R. L., …; Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's health initiative randomized controlled trial. Journal of the American Medical Association, 288, 321–333.
Rossouw J. E., Prentice R. L., Manson J. E., Stefanick M.L. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. Journal of the American Medical Association, 297, 1465–1477.
Santen R. J. (2015). Vaginal administration of estradiol: Effects of dose, preparation and timing on plasma estradiol levels. Climacteric, 18, 121–134.
Schmidt P. (2012). The 2012 hormone therapy position statement of the North American Menopause Society. Menopause (New York, NY), 19, 257.
Shanafelt T. D., Barton D. L., Adjei A. A., Loprinzi C. L. (2002). Pathophysiology and treatment of hot flashes. Mayo Clinic Proceedings, 77, 1207–1218.
Smith N. L., Blondon M., Wiggins K. L., Harrington L. B., van Hylckama Vlieg A., Floyd J. S., Psaty B. M. (2014). Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Internal Medicine, 174, 25–34.
Sood R., Shuster L., Smith R., et al. (2011). Counselling postmenopausal women about bioidentical hormones: Ten discussion points for practicing physicians. JABFM. 24(2):202–210.
Spoletini I., Vitale C., Pelliccia F., Fossati C., Rosano G. M. C. (2014). Androgens and cardiovascular disease in postmenopausal women: A systematic review. Climacteric, 17, 625–634.
Sprague B., Trentham-Dietz A., Cronin K. (2012). A sustained decline in postmenopausal hormone use: Results from the National health and Nutrition examination survey, 1999-2010. Obstetrics and Gynecology, 120, 595–603.
Stevenson J. C. (2009). Type and route of estrogen administration. Climacteric, 12 (suppl 1), 86–90.
Studd J., Panay N. (2004). Hormones and depression in women. Climacteric, 7, 338–346.
Wierman M. E., Arlt W., Basson R., Davis S. R., Miller K. K., Murad M. H., Santoro N. (2014). Androgen therapy in women: A reappraisal: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 99, 3489–3510.
Women's Health Initiative. (2017). Hormone therapy trials. Retrieved from https://www.whi.org/about/SitePages/HT.aspx. Accessed June 17, 2018.
Women's Health Initiative Steering Committee. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 291, 1701–1712.